What is MapLight Therapeutics, Inc. 's financing cash flow?

MapLight Therapeutics, Inc. (MPLT) reported financing cash flow of -$6.85M in Q1 2026.

What does financing cash flow mean?

Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.

MapLight Therapeutics, Inc. MPLT Financing Cash Flow

Financing Cash Flow at other companies

Bristol-Myers SquibbBMY

-$1.56B-57.1%

Johnson & JohnsonJNJ

$530M-94.9%

Neurocrine BiosciencesNBIX

-$86.1M+27.0%

Acadia PharmaceuticalsACAD

$4.23M+130%

AbbVieABBV

$919M+173%

LBR

LB Pharmaceuticals Inc Common StockLBRX

$93.83M—

Other financials

Income statement

See full

Operating income-$64.5M-174%

Net income-$60.7M-172%

EPS (diluted)-$1.34+95.4%

Balance sheet

See full

Cash & equivalents$55.7M—

Total debt$5.6M—

Total equity$399.8M+285%

Total assets$418.8M—

Cash flow

See full

Operating cash flow-$51.2M-100%

CapEx$24.0K—

Free cash flow-$51.2M—

Valuation

See full

Market cap$1.39B+100%

Enterprise value$1.34B—

Returns & leverage

See full

Return on equity-216.8%—

Debt / equity0×—

Current ratio22.9×—

Where this comes from

Reported directly by MapLight Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.

The official record: MapLight Therapeutics, Inc. ’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about MapLight Therapeutics, Inc. 's financing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is MapLight Therapeutics, Inc. 's financing cash flow?: MapLight Therapeutics, Inc. (MPLT) reported financing cash flow of -$6.85M in Q1 2026.
What does financing cash flow mean?: Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.